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ABSTRACT
We often seek to estimate the causal effect of an exposure on a particular outcome in both randomized
and observational settings. One such estimation method is the covariate-adjusted residuals estimator,
which was designed for individually or cluster randomized trials. In this manuscript, we study the
properties of this estimator and develop a new estimator that utilizes both covariate adjustment
and inverse probability weighting. We support our theoretical results with a simulation study and
an application in an infectious disease setting. The covariate-adjusted residuals estimator is an
efficient and unbiased estimator of the average treatment effect in randomized trials; however, it is
not guaranteed to be unbiased in observational studies. Our novel estimator, the covariate-adjusted
residuals estimator with inverse probability weighting, is unbiased in randomized and observational
settings, under a reasonable set of assumptions. Furthermore, when these assumptions hold, it provides
efficiency gains over inverse probability weighting in observational studies. The covariate-adjusted
residuals estimator is valid for use in randomized trials, but should not be used in observational
studies. The covariate-adjusted residuals estimator with inverse probability weighting provides an
efficient alternative for use in randomized and observational settings.
Estimating the effect of an exposure on a population has a long history. In 1855, John Snow compared the mortality
rates of households in London by the company that supplied their water to locate the source of a cholera epidemic. [1] In
1881, Louis Pasteur inoculated 50 sheep with anthrax, 25 of whom had been vaccinated; the vaccinated sheep survived
as the unvaccinated died, providing evidence that his anthrax vaccine was effective. [2] In 1948, Austin Bradford Hill
conducted the first modern randomized clinical trial, to evaluate a treatment for pulmonary tuberculosis, [3, 4] and later
formulated guidelines for researchers and practitioners to transition from thinking in terms of statistical association
to those of causation. [5] Since then, there has been a proliferation of methods to determine the exposure effects in
randomized trials and observational studies. [6–18]
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One such method is the covariate-adjusted residuals estimator (CARE), which was formulated to estimate the effect of
an exposure on an outcome of interest in individually randomized or cluster randomized trials. [14,19,20] To implement
CARE, researchers first predict the outcome using baseline covariates that influence the outcome, while leaving out
the exposure. Then they find the average residual for each group; this error can be the difference between or the ratio
of the observed values versus predicted values (i.e., the prediction error). The CARE estimate of the exposure effect
is the discrepancy between the average residuals in each group. In a randomized trial setting, [19] used parametric
regression models to predict the outcome as a function of baseline covariates, and demonstrated that while maintaining
confidence interval coverage, CARE could increase the statistical power over an unadjusted estimator, which is the
average difference (ratio) in outcomes between randomized groups. [20] showed that CARE made accurate estimates of
the effect size in cluster randomized trials, even when there were small numbers of clusters and moderate imbalances
in the distribution of predictive covariates. Most recently, CARE was used to investigate the effect of a Universal
Test-and-Treat intervention on HIV incidence in a large cluster randomized trial in Zambia and South Africa. [21] To
the best of our knowledge, the properties of CARE in a randomized trial have not been evaluated non-parametrically.
In observational settings, CARE is commonly used in ecology under the name ‘residual index’, [22–27] although it
has received some criticism. [28, 29] In the ecological field of allometry, researchers have used the residual index to
estimate the association of an exposure on the body mass of an organism, often in observational settings rather than
randomized trials. While there are domain-specific questions about whether ordinary least squares linear regression is
being used appropriately in allometry, [28] others have questioned the statistical validity of the residual index under
any circumstances. In particular, [29] stated that “even if the assumptions of the linear model hold for the original
variables, they will not hold for the residuals” and thus “the ‘residual index’ should never be used for statistical analyses
of condition or any other variable”. To the best of our knowledge, there has been no statistical theory presented to date
to support the continued use of the residual index, and thus CARE, in an observational setting.
In this manuscript, we provide new non-parametric theory that shows CARE is an unbiased estimator of the effect
of a binary exposure in randomized trials, but a biased estimator in most observational settings of interest. We also
provide the conditions in which CARE is a consistent estimator and asymptotically normal. Our work supplements and
generalizes existing parametric results from [19] for randomized trials and establishes new theory for observational
studies. We compare CARE to existing estimators and introduce a novel estimator for use in both randomized and
observational settings; CARE-IPW, our new estimator, combines CARE with methods using inverse probability
weighting. [7, 10, 30] We prove CARE-IPW is an unbiased estimator in both randomized trials and observational
settings, and provide the conditions for consistency and asymptotic normality. We support these theoretical results with
a simulation study.
As an illustration, we apply these methods to real data to estimate the effect of bednets on childhood mortality in a cluster
randomized trial in Ghana as originally published by [31] and discussed in [14, 20]. In this trial, the Kassena-Nankana
region of Ghana was divided into 96 clusters, 48 of which were randomly selected to receive impregnated bednets
in June 1993. From July 1993 to June 1995, children aged 6-59 months were surveilled until they died (the primary
outcome), they migrated out of the study area, they turned 60 months of age, or the end of the follow-up period was
reached. The clusters had 138 to 439 children each, with an average of 274.4 children. The data includes age in months
at time of enrollment, sex, outcome, years of follow-up, and the cluster-level exposure assignment for each child. To
improve the precision of their analysis, [31] used CARE to adjust for the imbalanced age distributions between the
exposure levels. The authors found that bednets were associated with an all-cause child mortality rate ratio of 0.83 (95%
CI: 0.69-1.00). [14] repeated this analysis using both age and sex as covariates and compared the estimated rate ratio
from CARE to that of an unadjusted analysis. Both the CARE rate ratio (RR: 0.844, 95% CI: 0.713, 0.999) and rate
difference (RD: -4.26, 95% CI: -8.76, 0.23) estimates indicated a stronger association than that found by the unadjusted
estimator (RR: 0.859, 95% CI: 0.721, 1.023; RD: -3.95, 95% CI: none provided). [14] We will use this case study as an
example when describing the causal framework and statistical theory and as our real data application.
1 Causal Roadmap
Did bednets reduce childhood mortality in Ghana? This is a common structure for a causal scientific question: how
would a change in an exposure (e.g. bednets) change an outcome (e.g. childhood mortality). As a result, answering
causal questions require a different approach than descriptive or associative questions. For example, a descriptive
analysis may provide point and uncertainty estimates for the childhood mortality in clusters that actually received
bednets and in clusters that did not receive bednets. If we were interested in predicting childhood mortality, we would
want to know whether including a covariate for bednets added value to predictions that may use other information
(such as age and sex), regardless of whether that relationship was causal or associative. Answering the causal question
requires a deeper understanding of the system that generates the exposure and the outcome, as well as the influence of
additional covariates.
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Figure 1: Causal diagrams for randomized trials (a) and observational studies (b). These diagrams give a visual
representation of the relationships between the variables in a causal model. Arrows are drawn from a potential cause to
an effect. In a completely randomized trial setting, the exposure A is generated independently of all other variables and
the outcome Y may be influenced by both the exposure A and a set of baseline covariates WY . In an observational
setting, the exposure A is no longer randomized, but instead is influenced by baseline covariates. Some of these
covariates WC also influence Y , thus confounding the relationship between the exposure A and the outcome Y . Other
covariates WA only influence the exposure A and not the outcome Y ; as before some covariates WY only influence
the outcome Y and not the exposure A. (For simplicity, other unmeasured sources of variation are omitted; see the
Supplemental Material for a complete graph).
Several conceptual and analytic frameworks exist and can guide our answering of causally motivated questions.
[11, 32–42]. Here, we review the Causal Roadmap of [40] and use the bednet example for illustration. The key steps
of the Causal Roadmap are representing knowledge of the data generating process (represented by a causal model);
specifying the quantity that answers the scientific question (the causal parameter); evaluating the assumptions required
to link the causal quantity to a well-defined function of the observed data distribution (the statistical parameter which
may or may not be identifiable); and finally obtaining a point estimate and inference of the statistical parameter.
A causal model is a structural framework for expressing the relationships between variables in a given setting. [37,43–46]
A causal model can be expressed graphically as a diagram, where variables are connected by edges (arrows) that
originate at a potential cause and terminate at the effect. Figure 1a is a diagram representing a randomized trial, like
that of our case study, where A is a binary exposure (A = 1 if the cluster received the bednet intervention, A = 0 if the
cluster did not) and WY is the set of baseline covariates (the average age and percentage of children who are female for
each cluster) that may influence the outcome Y (childhood mortality). There are no edges pointing to the exposure A
because the randomization procedure makes the allocation of exposure independent of all other covariates. (A diagram
including unmeasured variables is depicted in the Supplementary Materials.) For this experimental setting, we assume
that this causal model describes the data generating process for each cluster and that clusters are causally independent
(i.e. the outcome for one cluster is only influenced by that cluster’s exposure and baseline covariates and independent of
other clusters’ exposures, baseline covariates, and outcomes.)
In an observational setting (as portrayed in Figure 1b), the allocation to the exposure A is not randomized and is
potentially influenced by the baseline covariates. In addition to the covariates WY that influence the outcome Y , but
not the exposure A, there are two new subsets of covariates. One subset of covariates WA only influence the exposure
A, but not the outcome Y . The other subset are confounding covariates WC that influence both the exposure A and the
outcome Y and thus obscure the isolation of the causal effect of interest. As a running example, suppose bednets are
distributed to clusters by the determination of local health officials instead of at random. In this scenario, consider a
new baseline covariate: mosquito abundance. Places with greater mosquito abundance prior to the intervention may be
higher risk for infectious diseases and future childhood mortality and public health officials would want to concentrate
their efforts in these areas. Thus mosquito abundance is a confounding covariate, as it is a common cause of both the
outcome and the exposure.
With the causal model specified, we can translate our scientific question into a causal parameter. We assume that the
relationships within the causal model are autonomous, meaning that changing one relationship does not change the
other relationships, although changes may result in different effects downstream. [37, 44] Therefore, we could modify
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the way in which the exposure is generated and see resulting changes in the outcome. Specifically, we could intervene
to give impregnated bednets to a cluster (i.e. set A = 1) and generate the counterfactual (potential) outcome Y (1) for
that cluster. Likewise, we could intervene to put the same cluster in the unexposed group (i.e. set A = 0) and generate
the counterfactual (potential) outcome Y (0) for that cluster. With these counterfactual outcomes, we translate this
scientific question into a well-defined causal quantity, specifically the average treatment effect (ATE):
ATE = E[Y (1)− Y (0)]. (1)
The ATE is the expected difference in the average childhood mortality rate if all of the clusters in our target population
received impregnated bednets (Y (1)) and if none of the clusters received impregnated bednets (Y (0)). We cannot
directly estimate this parameter because we only observe the outcomes Y corresponding to the actual exposures A and
not both counterfactual outcomes. Thus, we need to outline the conditions and assumptions necessary to identify the
causal parameter as a statistical parameter of the observed data distribution.
In an observational setting, suppose our observed data consist of confounding covariates WC , the exposure indicator A,
and the outcome Y ; we denote the observed data as O = (WC , A, Y ) and assume we have n independent, identically
distributed (i.i.d.) copies from some distribution P. In this setting, we use the difference in conditional expectations
between the exposed and unexposed, adjusted for and averaged across the measured confounding covariates, as the
statistical parameter:
Ψobs(P) = EWC
[
E(Y | A = 1,WC)− E(Y | A = 0,WC)]. (2)
This statistical parameter Ψobs(P) is known as the “G-computation identifiability result”, which identifies the ATE
under two assumptions. [11] First, there must be no unmeasured confounding between the exposure and the outcome:
Y (a) ⊥ A |WC . Second, the ‘positivity assumption’, which states that each possible strata of measured confounding
covariates has a non-zero probability of being in each exposure group (P(A = a|WC = wC) > 0,∀wC ∈ P(WC =
wC) > 0), must hold. [47] In our example, the statistical parameter Ψobs(P) is the expected difference in the childhood
mortality rate between clusters with and without bednets adjusting for common causes.
In a randomized trial, the process for allocating units to the exposure is truly random (i.e. a coin flip). Therefore, the
assumptions of no unmeasured confounding and positivity are satisfied naturally by the study design. Therefore, in this
setting, we can identify the ATE with the target statistical parameter ΨRCT (P), the difference in the expectation of the
outcome between exposure groups:
ΨRCT (P) = E(Y |A = 1)− E(Y |A = 0). (3)
The statistical parameter ΨRCT (P) can be consistently estimated using the difference in the average outcome between
the exposure groups, also known as the ‘unadjusted estimator’: [32]
Ψˆunadj(Pˆ) =
1
n1
∑
i∀Ai=1
Yi − 1
n0
∑
i∀Ai=0
Yi = Eˆ(Y |A = 1)− Eˆ(Y |A = 0), (4)
where Pˆ is the empirical distribution; na is the number of units (i = 1, . . . , n = n0 + n1) in exposure level A = a, and
Eˆ(Y |A = a) is an estimate of the expected outcome in exposure group A = a. In the bednet cluster randomized trial,
the unadjusted estimate is the difference between the average mortality rate for clusters assigned to receive bednets and
the average mortality rate for clusters not assigned to receive bednets, as illustrated in Figure 2a.
In observational settings, the exposure allocation is no longer random, and we have to account for common causes of
the exposure A and outcome Y . If WC captures all those common causes (i.e. there is no unmeasured confounding)
and there is sufficient variability in the exposure within possible strata of WC (i.e. positivity holds), then the inverse
probability weighting (IPW) estimator can be used to estimate the statistical parameter Ψobs(P): [7, 30]
ΨˆIPW (Pˆ) =
1
n
n∑
i=1
(
I(Ai = 1)
Pˆ(A = 1 |WCi )
− I(Ai = 0)
1− Pˆ(A = 1 |WCi )
)
Yi, (5)
which controls for the confounding covariates through estimates of the conditional probability of receiving the exposure,
called ‘propensity scores’ Pˆ(A = 1 | WC). [10] Intuitively, the IPW estimator up-weights exposure-covariate
combinations that are rare, relative to a randomized trial, and down-weights exposure-covariate combinations that are
more common, relative to a randomized trial. If the propensity scores are consistent for the true conditional probability
of exposure given common causes P(A = 1 | WC), the IPW estimator is consistent for the statistical parameter
Ψobs(P). Notably, the propensity scores do not need to account for other covariates that only influence the exposure
WA.
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IPW can also be used in randomized trials, and in that setting estimating the known propensity score can lead to
efficiency gains over the unadjusted estimator. [18, 48, 49] In the bednet cluster randomized example, we used a logistic
regression with independent variables for average age and the proportion of children that are female to estimate the
probability of bednet assignment for each cluster Pˆ(A = 1 |WY ). Despite randomization, we found that the estimated
propensity scores ranged from 0.22 to 0.72 and were higher for clusters with lower average age than for clusters with
higher average age. In the study, younger clusters were, by chance, more likely to receive the bednet intervention than
older clusters. When obtaining a point estimate by taking the average difference in weighted outcomes, intervention
clusters with higher average ages were assigned greater weight, as are control clusters with lower average ages (Figure
2b).
2 The covariate-adjusted residuals estimator (CARE)
The covariate-adjusted residuals estimator (CARE) was proposed as a method to estimate the ATE in randomized
trials. [14, 19, 20] First, the outcome Y is predicted using only the baseline covariates WY and not the exposure A,
giving us predicted values Eˆ(Y |WY ). Next, residuals are derived as the difference between the observed outcome and
the predicted one. Finally, the difference in the average residuals between exposure groups provides a point estimate:
ΨˆCARE(Pˆ) =
1
n1
∑
i∀Ai=1
[
Yi − Eˆ(Y |WYi )
]
︸ ︷︷ ︸
Average residual for exposed
− 1
n0
∑
i∀Ai=0
[
Yi − Eˆ(Y |WYi )
]
︸ ︷︷ ︸
Average residual for unexposed
(6)
=
1
n
n∑
i=1
(
I(Ai = 1)
Pˆ(A = 1)
− I(Ai = 0)
Pˆ(A = 0)
)(
Yi − Eˆ(Y |WYi )
)
, (7)
where the number of units at each exposure level is equal to the total number of units times the empirical probability of
exposure na = n×Pˆ(A = a). To obtain the predictions of the outcome in the absence of the exposure Eˆ(Y |WY ), [14]
recommend using Poisson regression for event rates, logistic regression for binary outcomes, and linear regression for
continuous outcomes.
In the bednet cluster randomized example, we used Poisson regression to estimate the child mortality rate for each
cluster with independent variables for average age and the proportion of children that are female, but not for bednet
assignment. The point estimate from CARE is then the difference between the average residual for intervention clusters
and the average residual for control clusters (Figure 2c)
Theorem 2.1 In a randomized trial, the covariate adjusted residuals estimator (CARE) is an unbiased estimator of
the target statistical parameter ΨRCT (P) = E(Y |A = 1)− E(Y |A = 0) and thus the average treatment effect (ATE)
because the identifiability assumptions hold by design.
The proof is given in Appendix A. Briefly, consider the following estimating function of the observed data O =
(WY , A, Y ) and parameter ψ: [17, 50]
D(O;ψ) =
(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)(
Y − E(Y |WY ))− ψ (8)
D is an unbiased estimating function for ΨRCT (P) = ψRCT in that when ψ = ψRCT its expectation is zero:
E[D(O;ψRCT ] = 0 (proof in Appendix A). The corresponding estimating equation is given by
0 =
1
n
n∑
i=1
D(Oi;ψ)
and we obtain a point estimate from CARE by solving this estimating equation. In other words, ψˆCARE is the solution
satisfying 0 = 1/n
∑n
i=1 Dˆ(Oi; ψˆ
CARE), as shown in Equation 7.
CARE requires estimation of both the marginal probability of the exposure P(A = 1) and conditional expectation of
the outcome, given the covariates E(Y | WY ). Since the exposure mechanism is always consistently estimated in
randomized trials, CARE will be consistent for ΨRCT (P) in a trial setting. Under regularity conditions, [17, 50] the
Central Limit Theorem applies, and CARE is asymptotically normal with variance well-approximated by the sample
variance of Dˆ(O; ψˆCARE) divided by sample size n. This simple variance estimator can be used for construction of
Wald-Type 95% confidence intervals and testing the null hypothesis.
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When accounting for predictive covariates WY that are imbalanced by chance between the two randomized groups,
we expect CARE to provide efficiency gains over the unadjusted estimator. [6, 8, 9, 13, 15, 16, 18] When the predicted
values of the outcome Eˆ(Y |WY ) are a constant value (e.g. zero or the mean of all observations Eˆ(Y )), then CARE is
equivalent to the unadjusted estimator (proof in Appendix A). Thus, the unadjusted estimator could be considered a
special case of CARE.
Theorem 2.2 In most observational settings of interest, the covariate adjusted residuals estimator (CARE) is a biased
estimator of the target statistical parameter Ψobs(P) = EWC
[
E(Y |A = 1,WC)− E(Y |A = 0,WC)].
The proof is given in Appendix B. Briefly, the expectation of the CARE estimating function (Equation 8) for Ψobs(P) =
ψobs is
E
[
D(O;ψobs)
]
= ψRCT − E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
E(Y |WC)
]
− ψobs.
For this expectation to be zero, we would need the residual difference between the “unadjusted” estimand ψRCT and
the “adjusted” estimand ψobs to be captured by the average difference in the weighted predictions in the absence of the
exposure E(Y |WC). There is no reason to believe this would generally be the case. Instead, we can only expect this to
hold under the strong null, where ψobs = 0 and E(Y | A,WC) = E(Y |WC). When the null is false (i.e. there is an
exposure effect), there might also be scenarios where we get some bias cancellation, but this cannot be proven under a
non-parametric statistical model. Thus, CARE is only guaranteed to be a consistent estimator of Ψobs(P) when the null
is true and conditional mean outcome E(Y | A,WC) = E(Y |WC) is consistently estimated. Since we do not know
a priori whether or not the null hypothesis is true (which is presumably why we are trying to estimate the exposure
effect), we do not recommend that CARE be used in observational settings.
3 Improving upon CARE with inverse probability weighting
As previously discussed, the inverse probability weighting (IPW) estimator controls for measured confounders by
up-weighting observations that have a rare exposure-covariate combination (relative to a randomized trial) and down-
weighting those with a common exposure-covariate combination (again relative to a randomized trial) using the
estimated propensity scores Pˆ(A = 1 | WC). This suggests that we may improve CARE (Equation 7) for use in
observational settings by replacing the empirical probabilities of exposure Pˆ(A = 1) with estimated propensity scores
Pˆ(A = 1 | WC). To our knowledge, such an estimator has not been previously proposed or explored, and thus we
name it “covariate-adjusted residuals estimator with inverse probability weighting” (CARE–IPW):
ΨˆCARE−IPW (Pˆ) =
1
n
n∑
i=1
(
I(Ai = 1)
Pˆ(A = 1 |WCi )
− I(Ai = 0)
Pˆ(A = 0 |WCi )
)(
Yi − Eˆ(Y |WCi )
)
. (9)
The CARE–IPW estimate is the difference in the weighted average of the residuals for the intervention group and for
the control group.
The CARE–IPW estimator can also be applied to randomized trials by replacing the confounding covariates WC , which
are not present in randomized trials, with the covariates that affect the outcome WY . In the bednet cluster randomized
trial example, we used Poisson regression to estimate the child mortality rate for each cluster E(Y | WY ), as in the
CARE estimator, and a logistic regression to estimate the propensity scores for bednet assignment P(A = 1 |WY ), as
in the IPW estimator (Figure 2d).
Theorem 3.1 In an observational setting, the covariate-adjusted residuals estimator with inverse probability weighting
(CARE–IPW) is an unbiased estimator of the target statistical parameter Ψobs(P) = EWC
[
E(Y |A = 1,WC) −
E(Y |A = 0,WC)]. In randomized trials where the identifiability assumptions hold by design and Ψobs(P) = ΨRCT (P),
CARE–IPW is an unbiased estimator of the average treatment effect (ATE).
The proof is given in Appendix C. Briefly, consider the following estimating function of the observed data O =
(WC , A, Y ) and parameter ψ:
D∗(O;ψ) =
(
I(A = 1)
P(A = 1 |WC) −
I(A = 0)
P(A = 0 |WC)
)(
Y − E(Y |WC))− ψ (10)
D∗ is an unbiased estimating function for Ψobs(P) = ψobs in that when ψ = ψobs its expectation is zero:
E[D∗(O;ψobs] = 0 (proof in Appendix C). The corresponding estimating equation is given by
0 =
1
n
n∑
i=1
D∗(Oi;ψ)
6
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We obtain a point estimate from CARE–IPW by solving this estimating equation. In other words, ψˆCARE−IPW is the
solution satisfying 1/n
∑n
i=1 Dˆ
∗(Oi; ψˆCARE−IPW ), as shown in Equation 9.
CARE–IPW requires estimation of both the propensity score P(A = 1 | WC) and conditional expectation of the
outcome, given the covariates E(Y | WC). CARE–IPW is consistent when the propensity score P(A = 1 | WC)
is consistently estimated, or when the null is true and conditional mean outcome E(Y | A,WC) = E(Y | WC) is
consistently estimated. Under regularity conditions, [17, 50] the Central Limit Theorem applies, and CARE–IPW is
asymptotically normal with variance well-approximated by the sample variance of Dˆ∗(O; ψˆCARE−IPW ) divided by
sample size n. By predicting the outcome with the covariates Eˆ(Y |WC), we expect CARE-IPW to provide efficiency
gains over the IPW estimator.
Each of the estimators described in this paper can be characterized as special cases of CARE–IPW. CARE–IPW reduces
to CARE when the propensity scores are estimated with the empirical probability of exposure. CARE–IPW reduces to
IPW when the predicted values of the outcome are all zero. CARE–IPW reduces to the unadjusted estimator when both
of the above conditions are met.
4 Simulation Study
In this section, we use a simulation to compare the performance of the unadjusted estimator, IPW, CARE, and CARE–
IPW in a randomized trial as well as an observational setting. We consider a synthetic data-generating process with
a binary exposure and a binary outcome. In the randomized setting, three covariates affect the outcome. In the
observational setting, the relationship between the exposure and the outcome is confounded by two covariates. In both
settings, there is no unmeasured confounding and positivity holds by design; estimates can, therefore, be interpreted
causally.
We compare the performance of the estimators using bias, Monte Carlo standard error, average standard error estimate,
confidence interval coverage, power, and type I error. Let ψˆs denote the point estimate in simulation s, s = 1, . . . , S.
Bias is the average difference between the point estimate and the statistical parameter 1S
∑S
s=1 ψˆs −ψ, where ψ is ψobs
in the observational setting and ψrct in the randomized setting. Monte Carlo standard error is the standard error of
the point estimates across simulations
√
V ar(ψˆ1:S). The average standard error estimate is the mean of the estimated
standard errors across simulations 1S
∑S
s=1
√
νs, where νs is the influence curve-based estimate of the variance in
simulation s. Confidence interval coverage is the proportion of 95% confidence intervals that covered the statistical
parameter ψ across all simulations. Power is the proportion of simulations that the estimator rejected the null hypothesis
of no exposure effect when there was an exposure effect. Type I error is the proportion of simulations that the estimator
rejected the null hypothesis of no exposure effect when the null hypothesis was true.
All simulations were run using R version 3.4.3. [51] Simulations were run in parallel on 15 cores on a remote
server. To maintain reproducibility and to make sure that the same samples were drawn for each scenario (with
and without an effect in randomized and observational settings) across simulations, we set a seed for the random
number generator for each simulation based on the simulation number. The code used for this project can be found at
https://doi.org/10.5281/zenodo.3517241.
4.1 Setup
To study the finite sample properties of CARE and CARE–IPW relative to those of the unadjusted and IPW estimators,
we designed a synthetic simulation with binary exposures and outcomes.
Consider an experiment with 96 units. For each unit in the sample, we generate four independent baseline covariates:
W1 ∼ Normal(0, 1), W2 ∼ Normal(0, 1), W3 ∼ Uniform(0, 1), and W4 ∼ Bernoulli(0.5). We simulate a
randomized trial where the exposure A is assigned with probability 0.5 as well as an observational setting where the
exposure is assigned with a probability given by logit−1[1−0.75 ·W1−2 ·W4+0.5 ·W2]. Each unit’s counterfactual
outcomes, Y (1) and Y (0), are generated as
Y (A) = Bernoulli
(
logit−1[−0.25 + 0.5 ·W1− 1 ·W3 + 2 ·W4− 1.25 ·A− 0.5 ·A ·W3])
by deterministically setting the exposure to A = 1 and A = 0, respectively. The average treatment effect is calculated
by taking the mean difference in the counterfactual outcomes for a population of 100,000 units. We also simulate a
scenario under the null hypothesis of no exposure effect by setting the counterfactual outcome with the exposure Y (1)
equal to the counterfactual outcome without the exposure Y (0).
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We implement the unadjusted estimator as the difference in average outcomes between exposed and unexposed units
(Equation 4). When estimating the propensity score, required for IPW and CARE–IPW, we use a logistic regression
with main terms for W1 and W4, which are the confounders in the observational setting. For the outcome prediction,
which is required for CARE and CARE–IPW, we use a logistic regression with main terms for W1, W3, and W4,
which corresponds to the correctly specified regression under the null.
4.2 Results
Table 1 provides a comparison of the performance of the estimators over S=5,000 repetitions of the simulation. When
there is an effect, the intervention A led to a -28.1% average reduction in the outcome.
All estimators are unbiased in the randomized trial setting. The 95% confidence interval coverage for each algorithm is
close to or above the nominal level. Improvements in Monte Carlo standard error, average standard error, and statistical
power over both the unadjusted and the IPW estimators are achieved by both CARE and CARE–IPW.
Table 1: Results for the estimators for the simulation by trial type and exposure effect. The covariate-adjusted residuals
estimator (CARE) uses a logistic regression with W1, W3, and W4 to predict the outcome. The inverse probability
of weighting (IPW) estimator uses a logistic regression with W1 and W4 to estimate the propensity scores. CARE
with inverse probability weighting (CARE–IPW) the same regression as CARE to predict the outcome and the same
regression as IPW to estimate the propensity scores.
Trial Exposure Estimator Bias MC SE Average SE
95% CI
cover-
age
Power/
Type I
error
RCT Effect
CARE–IPW 0.003 0.092 0.092 94.5% 85.4%
CARE 0.008 0.090 0.090 94.4% 85.3%
IPW -0.001 0.094 0.148 99.7% 46.2%
Unadj -0.002 0.101 0.101 94.3% 78.1%
RCT Null
CARE–IPW 0.000 0.093 0.090 94.1% 5.9%
CARE 0.000 0.091 0.089 94.4% 5.6%
IPW 0.000 0.095 0.167 99.9% 0.1%
Unadj -0.000 0.104 0.103 94.4% 5.6%
Obs Effect
CARE–IPW 0.000 0.115 0.115 94.5% 71%
CARE 0.062 0.082 0.081 87.4% 75.6%
IPW -0.005 0.126 0.164 98.7% 44.6%
Unadj -0.197 0.088 0.089 41.7% 100%
Obs Null
CARE–IPW -0.004 0.107 0.102 94.1% 5.9%
CARE -0.003 0.079 0.087 96.7% 3.3%
IPW -0.005 0.124 0.197 99.6% 0.4%
Unadj -0.219 0.100 0.099 39.7% 60.3%
When there is an effect in the observational setting, the unadjusted estimator is markedly biased with low confidence
interval coverage: 41.7%. By adjusting for confounders when predicting the outcome, CARE reduces but does not
eliminate bias and achieves confidence interval coverage of 87.4%, still much less than the nominal level. Through
consistent estimation of the propensity score and thereby control for the confounders, both the IPW estimator and
CARE–IPW are unbiased and achieve nominal to conservative confidence interval coverage. CARE–IPW is more
efficient and achieves higher statistical powerful than the IPW estimator: 71.0% vs. 44.6%, respectively.
When there is no effect in an observational setting, the unadjusted estimator is again biased with low confidence interval
coverage at 39.7%. Both CARE, and CARE–IPW are unbiased with nominal to conservative Type I error control and
greater precision than the IPW estimator. We note that under the null, CARE is expected to be consistent if the outcome
is correctly predicted, which it was here.
Altogether this simulation confirms the theoretical properties described in Sections 2-3.
5 Case study
In this section, we first reproduce the findings of [14], who compared CARE to the unadjusted estimator in the cluster
randomized trial to estimate the impact of impregnated bednets on child mortality in northern Ghana. [20, 31] Then we
apply the IPW estimator and CARE–IPW on the same data and discuss the results.
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5.1 Setup
In the original analysis, the researchers estimated the unadjusted and covariate-adjusted mortality rates for the exposed
and unexposed groups and compared them using the t-test. For the unadjusted estimator, the observed mortality rate (i.e.
the number of deaths per thousand follow-up years) was calculated for each cluster. The unadjusted estimate of the
ATE was equal to the difference in the average observed mortality rate between randomized arms (Figure 2a).
In the covariate-adjusted analysis, the researchers used a Poisson regression for mortality rate on the individual-level
data using age and sex as covariates, but not the cluster intervention assignment. From this regression, they predicted
the mortality rate per follow-up year for each child, which they then aggregated into cluster-level predicted mortality
rates per thousand follow-up years. The researchers found the residuals by taking the difference between the observed
and predicted mortality rates for each cluster. The CARE estimate of the ATE was equal to the difference in the average
of the residuals between randomized arms (Figure 2c). Hayes and Moulton used a t-test to generate confidence intervals
and conduct hypothesis testing.
We reproduce this analysis and extend it to include IPW and CARE–IPW (Figure 2b,d). While our point estimates of
the ATE for CARE and the unadjusted estimator are identical to those in Hayes and Moulton, we estimate the variance
using influence curve-based methods (Sections 2-3), which yield slightly different confidence intervals and p-values.
The IPW and CARE–IPW estimators require propensity scores, which we estimate with a main terms logistic regression
for the exposure at the cluster-level using average age in months and percent of children who are female as covariates.
For CARE–IPW, we use the same predicted values of the outcome from the individual-level regression as used for
CARE.
5.2 Results
The IPW and CARE–IPW estimates of the exposure effect are larger than the estimates from the unadjusted estimator
or CARE (Figure 3). As in the original analysis, we estimate a mortality rate difference between the exposed group and
the unexposed group of -3.95 (95% CI: -8.46, 0.56; p-value = 0.09) per thousand follow-up years using the unadjusted
estimator and -4.26 (95% CI: -8.67, 0.15; p-value = 0.06) per thousand follow-up years using CARE. Using IPW,
the estimated mortality rate difference is -5.37 (95% CI: -16.94, 6.2; p-value = 0.36) per thousand follow-up years.
For CARE–IPW the mortality rate difference is -5.08 (95% CI: -9.46, -0.7; p-value = 0.02) per thousand follow-up
years. As in the simulation study, the standard error estimates for the CARE and CARE–IPW are less than those of the
unadjusted and IPW. While IPW had the largest estimated effect size, it also had the largest estimated variance and
thereby widest confidence intervals of any estimator. The estimate made by CARE–IPW was larger than either the
unadjusted estimator or CARE and had the smallest variance estimate.
6 Discussion
In this paper, we (1) provide non-parametric statistical theory for the covariate-adjusted residuals estimator (CARE)
in randomized and observational settings, (2) propose a novel estimator, the covariate-adjusted residuals estimator
with inverse probability weighting (CARE–IPW), and (3) support theoretical results with a simulation study and an
application to a cluster randomized trial. Specifically, we prove that CARE is consistent for the average treatment effect
(ATE) in randomized studies. We also prove that CARE is not consistent for the ATE in most observational settings of
interest (e.g. when there is an exposure effect). We develop a new estimator, CARE–IPW, which is consistent for the
ATE in observational settings when the propensity scores are consistently estimated.
The simulation study supports our theoretical findings and suggests some advantages to using CARE–IPW rather than
CARE or the IPW estimator. In randomized trials, CARE and CARE–IPW achieved greater precision and statistical
power, compared to the other estimators, and maintained nominal confidence interval coverage. In observational
settings, CARE–IPW is consistent for the statistical parameter Ψobs(P) when accounting for the confounding covariates
in the propensity score model and has greater statistical power and less variability than the IPW estimator. CARE is
biased in observational settings with an exposure effect.
While CARE–IPW improves on CARE and IPW, it is not a “double robust estimator”, such as targeted maximum
likelihood estimation and augmented inverse probability weighting. [12, 48, 52, 53] A double robust estimator is
consistent for Ψobs(P) if either the outcome predictions (which often include the exposure as well as baseline covariates)
or the propensity scores is consistently estimated and is the most efficient estimator if both are. Similar to the IPW
estimator, CARE–IPW is consistent for if and only if the propensity score is consistently estimated. By incorporating
predictions of the outcome, CARE–IPW is expected to be more efficient than IPW.
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One advantage to using CARE–IPW rather than another method is that researchers do not need to specify the relationship
between the exposure and the outcome. This can be beneficial when there is a complex relationship between the
exposure and outcome, such as multiple non-linear interactions with other covariates that augment the strength of the
exposure.
As with the IPW estimator, CARE–IPW may have stability issues when estimated propensity scores approach zero or
one. [47] This could be resolved in one of a couple ways. Stabilized weights could be used to scale propensity scores
away from zero and one. [30] Alternatively, propensity scores could be replaced by incremental propensity scores
which relax the positivity assumption by looking at the effect of an intervention when propensity scores are uniformly
increased and decreased across all observations. [54]
The findings of this paper suggest that CARE is suitable for use in estimating the average treatment effect in randomized
trials, but not in observational settings. As an alternative to CARE, CARE–IPW has potential for use as an estimator in
observational settings; further research is warranted.
A Proof of Theorem 2.1
Suppose we are in a trial setting. Let WY denote the covariates that are predictive of the outcome, A be a binary
indicator of receiving the exposure, and Y be the outcome. We assume that we have n independent, identically
distributed copies of observed data O = (WY , A, Y ) with some distribution P. In the following, we assume discrete
random variables for simplicity; however, all summations generalize to integrals for continuous random variables. In a
randomized trial, our target statistical estimand is ΨRCT (P) = E(Y |A = 1)− E(Y |A = 0).
The expectation of the CARE estimating function (Equation 8) is
E [D(O;ψ)] =E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)(
Y − E(Y |WY ))]− ψ
=E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
Y
]
− E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
E(Y |WY )
]
− ψ
The first component of the expectation is equal to the target parameter in a randomized trial ΨRCT (P) = ψRCT :
E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
Y
]
=
∑
a,y
(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
yP(Y = y | A = a)P(A = a)
=
∑
y
P(A = 1)
P(A = 1)
yP(Y = y | A = 1)−
∑
y
P(A = 0)
P(A = 0)
yP(Y = y | A = 0)
=
∑
y
yP(Y = y | A = 1)−
∑
y
yP(Y = y | A = 0)
=E(Y |A = 1)− E(Y |A = 0)
=ψRCT
The second component of the expectation is 0:
E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
E(Y |WY )
]
=
∑
wY ,a,y
(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
yP(Y = y |WY = wY )P(A = a |WY = wY )P(WY = wY )
=
∑
wY ,y
[
P(A = 1 |WY = wY )
P(A = 1)
− P(A = 0 |W
Y = wY )
P(A = 0)
]
yP(Y = y |WY = wY )P(WY = wY )
In a randomized trial, we have P(A |WY ) = P(A), and thus the second component is zero.
Thus, when our parameter of interest is ψ = ψRCT , the expectation of the CARE estimating equation
E[D(O | ψRCT )] = ψRCT − 0− ψRCT = 0.
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This proves that in a trial setting the CARE estimating function is unbiased for the statistical parameter ψRCT , which
identifies the average treatment effect because identifiability assumptions hold by design.
Corollary 2.1.1: If the predicted outcome Eˆ(Y | WY ) is a constant (e.g. 0 or the sample average outcome), CARE
reduces to the unadjusted difference in mean outcomes.
Proof: Denote the predicted outcome Eˆ(Y |WY ) with a constant C, and let n1 and n0 denote the number of treated
and control units, respectively. Then we have
ΨˆCARE =
1
n
n∑
i=1
(
I(Ai = 1)
Pˆ(A = 1)
− I(Ai = 0)
Pˆ(A = 0)
)
(Yi − C)
=
1
n
n∑
i=1
(
I(Ai = 1)
Pˆ(A = 1)
− I(Ai = 0)
Pˆ(A = 0)
)
Yi − 1
n1
∑
i∈Ai=1
C − 1
n0
∑
i∈Ai=0
C
=
1
n
n∑
i=1
(
I(Ai = 1)
Pˆ(A = 1)
− I(Ai = 0)
Pˆ(A = 0)
)
Yi − n1
n1
C − n0
n0
C
=
1
n
n∑
i=1
(
I(Ai = 1)
Pˆ(A = 1)
− I(Ai = 0)
Pˆ(A = 0)
)
Yi.
B Proof of Theorem 2.2
Suppose we are in an observational setting. Let WC denote the confounding covariates, A be binary an indicator of
receiving the exposure, and Y be the outcome. We assume that we have n independent, identically distributed copies of
observed data O = (WC , A, Y ) with some distribution P. In the following, we assume discrete random variables for
simplicity; however, all summations generalize to integrals for continuous random variables. In an observational setting,
our target statistical estimand is Ψobs(P) = EWC
[
E(Y |A = 1,WC)− E(Y |A = 0,WC)].
Using the same steps as in the Proof for Theorem 2.1 (Appendix A), but replacing the predictive covariates WY with
the confounding covariates WC , the expectation of the CARE estimating function (Equation 8) in an observational
setting is given by
E [D(O;ψ)]
=E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
Y
]
− E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)
E(Y |WC)
]
− ψ
=ψRCT
−
∑
wC ,y
[
P(A = 1 |WC = wC)
P(A = 1)
− P(A = 0 |W
C = wc)
P(A = 0)
]
yP(Y = y |WC = wC)P(WC = wC)
− ψ
where ψRCT = E(Y |A = 1) − E(Y |A = 0) and where, due to confounding, P(A = a | WC = wC) 6= P(A = a).
When our parameter of interest is ψ = ψobs, the expectation E[D(O;ψobs] is generally not zero.
Under a non-parametric statistical model, we can only guarantee the expectation E[D(O;ψobs] is zero under the strong
null, where ψobs = 0 and E(Y | A,WC) = E(Y |WC):
E
[
D(O;ψobs)
]
= E
[(
I(A = 1)
P(A = 1)
− I(A = 0)
P(A = 0)
)(
Y − E(Y |WC))]− ψobs
= E
[(
P(A = 1 |WC)
P(A = 1)
− P(A = 0 |W
C)
P(A = 0)
)(
E(Y |A,WC)− E(Y |WC))]− ψobs
= 0 if E(Y |A,WC) = E(Y |WC) and ψobs = 0
When the null is false, there might also be some scenarios when E
[
D(O;ψobs)
]
= 0, but this cannot be proven under a
non-parametric statistical model. Thus, we conclude that the CARE estimating function is generally not an unbiased for
ψobs, even if the covariates WC , which are sufficient to control for confounding, are used to predict the outcome.
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C Proof of Theorem 3.1
Suppose we are in an observational setting. Let WC denote the confounding covariates, A be binary an indicator of
receiving the exposure, and Y be the outcome. We assume that we have n independent, identically distributed copies of
observed data O = (WC , A, Y ) with some distribution P. In the following, we assume discrete random variables for
simplicity; however, all summations generalize to integrals for continuous random variables. In an observational setting,
our target statistical estimand is Ψobs(P) = EWC
[
E(Y |A = 1,WC)− E(Y |A = 0,WC)].
The expectation of the CARE–IPW estimating function (Equation 10) is
E [D∗(O | ψ)] =E
[(
I(A = 1)
P(A = 1 |WC) −
I(A = 0)
P(A = 0| |WC)
)(
Y − E(Y |WC))]− ψ
=E
[(
I(A = 1)
P(A = 1 |WC) −
I(A = 0)
P(A = 0 |WC)
)
Y
]
− E
[(
I(A = 1)
P(A = 1 |WC) −
I(A = 0)
P(A = 0 |WC)
)
E(Y |WC)
]
− ψ
The first component of the expectation is equivalent to the IPW estimand and equal to the target parameter Ψobs(P) =
ψobs:
E
[(
I(A = 1)
P(A = 1 |WC) −
I(A = 0)
P(A = 0 |WC)
)
Y
]
=
∑
wC ,a,y
(
I(A = 1)
P(A = 1 |WC = wC) −
I(A = 0)
P(A = 0 |WC)
)
yP(Y = y | A = a,WC = wC)
× P(A = a |WC = wC)P(WC = wC)
=
∑
wC ,y
P(A = 1 |WC = wC)
P(A = 1 |WC = wC)yP(Y = y | A = 1,W
C = wC)P(WC = wC)
−
∑
wC ,y
P(A = 0 |WC = wC)
P(A = 0 |WC = wC)yP(Y = y | A = 0,W
C = wC)P(WC = wC)
= EWC
[
E(Y | A = 1,WC)− E(Y | A = 0,WC)
]
= ψobs
The second component of the expectation is 0:
E
[(
I(A = 1)
P(A = 1 |WC) −
I(A = 0)
P(A = 0 |WC)
)
E(Y |WC)
]
=
∑
wC ,a,y
(
I(A = 1)
P(A = 1 |WC = wC) −
I(A = 0)
P(A = 0 |WC = wC)
)
yP(Y = y |WC = wC)
× P(A = a |WC = wC)P(WC = wC)
=
∑
wC ,y
(
P(A = 1 |WC = wC)
P(A = 1 |WC = wC) −
P(A = 0 |WC = wC)
P(A = 0 |WC = wC)
)
yP(Y = y |WC = wC)P(WC = wC)
= 0
When our parameter of interest is ψ = ψobs, the expectation of the CARE–IPW estimating function is
E[D∗(O;ψobs)] = ψobs − 0− ψobs = 0
This proves that in an observational setting the CARE–IPW estimating function is unbiased for the statistical parameter
ψobs, which identifies the average treatment effect under the assumptions outlined in Section 1. In a randomized
trial, we have Ψobs(P) = ΨRCT (P), and thus the CARE-IPW estimating function is also unbiased when the exposure
mechanism is known.
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Figure 2: Estimates of the effect of bednets on childhood mortality rate using different methods; data obtained
from [14]. In all plots, the clusters are arranged by the average age of the children in the cluster (x-axis); blue triangles
denote clusters assigned to receive bednets (A = 1; intervention), and orange circles denote clusters not assigned
to receive bednets (A = 0; control). Despite randomization, there were imbalances in baseline covariates predictive
of the outcome (WY ) between arms. (a) The unadjusted estimate is the difference in the average child mortality
rate (Y ), per thousand follow-up years, between intervention clusters (dashed blue line) and control clusters (solid
orange line). (b) The inverse probability weighting (IPW) estimator gives greater weight to intervention clusters
with higher average ages and control clusters with lower average ages, as indicated by the size of the triangles and
circles. The point estimate from IPW is the difference in the average of the weighted outcomes between groups. (c)
The covariate-adjusted residuals estimator (CARE) uses predictions (Yˆ ) of the child mortality rates based on Poisson
regression with average age and proportion female as covariates. The point estimate from CARE is the difference in the
average residuals between intervention clusters and control clusters. (d) The covariate-adjusted residuals estimator with
inverse probability weighting (CARE–IPW) combines the weights from the IPW estimator with the residuals from
CARE. Specifically, the point estimate from CARE–IPW is the difference in the average of the weighted residuals
between groups.
16
A PREPRINT - OCTOBER 28, 2019
CARE−IPW
IPW
CARE
Unadjusted
−20 −10 0 10
Estimated difference in childhood mortality rate, per thousand person−years
Figure 3: The estimates and 95% confidence intervals for the effect of allocating bednets on childhood mortality
rate per thousand follow-up years; data obtained from [14]. The four algorithms are the unadjusted estimator, the
covariate-adjusted residuals estimator (CARE), the inverse probability weighting estimator (IPW), and CARE with
inverse probability weighting (CARE–IPW). While all estimates indicate that bednets cause a reduction in childhood
mortality, the CARE and CARE–IPW estimates are more precise than those of the unadjusted and IPW estimators.
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Figure 1: Causal diagrams for randomized trials (a) and observational studies (b) including measured and unmeasured
covariates. These diagrams give us a visual representation of the relationships between the variables in a causal
model. Arrows are drawn from a cause to an effect; dashed double-sided arrows indicate an unknown or unmeasured
relationship. In a randomized setting, the exposure of interest (A) is independent of all other variables and the outcome
of interest (Y ) is influenced by both A and a set of other covariates (WY ). Randomization also guarantees that the
unmeasured factors influencing A (UA) are independent of the unmeasured factors influencing WY (UWY ) and Y
(UY ). In an observational setting, A is no longer randomized, but instead influenced by other covariates. Some of these
covariates (WC) also influence Y , thus confounding the relationship between A and Y . Other covariates (WA) only
influence A and not Y . Without randomization any of the unmeasured covariates may have a relationship with any of
the other unmeasured covariates, as indicated by the dashed arrows around the perimeter of the diagram.
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